GlassScriptPhysician profile
Sydney Rotman
NPI 1487330809
$1,466.10
in general payments reported to CMS, 2019-2025
17 companies · $1,107 in 2025
The $1,107 reported for 2025 was more than what 88% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $191 · 2024: $168 · 2025: $1,107.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $750 · Food and Beverage: $716.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $750.00 |
| Food and Beverage | $716.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Davol INC. | $750.00 | 2025 | Surgiphor |
| Astrazeneca Pharmaceuticals LP | $149.10 | 2025 | Breztri |
| Averitas Pharma INC. | $115.92 | 2023 | Qutenza |
| Pfizer INC. | $96.62 | 2025 | |
| Novo Nordisk INC | $64.70 | 2023-2024 | Rybelsus |
| Exact Sciences Corporation | $39.02 | 2024-2025 | Cologuard Collection Kit |
| Inogen, INC. | $28.76 | 2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $28.24 | 2025 | Aralast |
| Janssen Pharmaceuticals, INC | $26.35 | 2023 | Xarelto |
| Corcept Therapeutics | $26.02 | 2024 | Korlym |
| Alexion Pharmaceuticals, INC. | $25.86 | 2023 | Strensiq |
| Janssen Biotech, INC. | $23.34 | 2025 | Tremfya |
| Abbvie INC. | $22.13 | 2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $21.85 | 2024 | |
| Recordati_rare_diseases_inc. | $20.37 | 2025 | Isturisa |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $14.49 | 2024 | Ofev |
| Lilly USA, LLC | $13.33 | 2024 | Mounjaro, Zepbound |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sydney Rotman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.